Overview

Safety and Preliminary Efficacy of IVMED-80 Eye Drops in Keratoconus Patients

Status:
Completed
Trial end date:
2020-07-08
Target enrollment:
Participant gender:
Summary
We investigated the use of a copper sulfate eye drop (IVMED-80) for the treatment of keratoconus. Preliminary laboratory data shows that the addition of copper sulfate increase crosslinking of the structural proteins of the cornea thereby halting the progressing corneal thinning and bulging seen in keratoconus. We conducted a Phase 1/2a study to evaluate the safety and preliminary efficacy of a 6-week and a 16-week regimen using IVMED-80 and studied its impact on ocular safety and the change/progression in patients' vision and clinical measurements.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
iVeena Delivery Systems, Inc.
Collaborator:
Codet Vision Institute